- Home
- AMAL vs REPL Comparison
AMAL vs REPL Comparison
Compare AMAL & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- REPL
- Stock Information
- Founded
- AMAL 1923
- REPL 2015
- Country
- AMAL United States
- REPL United States
- Employees
- AMAL N/A
- REPL N/A
- Industry
- AMAL Commercial Banks
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- REPL Health Care
- Exchange
- AMAL Nasdaq
- REPL Nasdaq
- Market Cap
- AMAL 937.6M
- REPL 239.0M
- IPO Year
- AMAL 2018
- REPL 2018
- Fundamental
- Price
- AMAL $29.75
- REPL $7.46
- Analyst Decision
- AMAL Buy
- REPL Buy
- Analyst Count
- AMAL 2
- REPL 10
- Target Price
- AMAL $38.50
- REPL $8.25
- AVG Volume (30 Days)
- AMAL 170.8K
- REPL 10.6M
- Earning Date
- AMAL 07-24-2025
- REPL 08-07-2025
- Dividend Yield
- AMAL 1.88%
- REPL N/A
- EPS Growth
- AMAL 3.73
- REPL N/A
- EPS
- AMAL 3.34
- REPL N/A
- Revenue
- AMAL $305,130,000.00
- REPL N/A
- Revenue This Year
- AMAL $11.72
- REPL N/A
- Revenue Next Year
- AMAL $12.48
- REPL N/A
- P/E Ratio
- AMAL $8.94
- REPL N/A
- Revenue Growth
- AMAL 4.49
- REPL N/A
- 52 Week Low
- AMAL $25.03
- REPL $2.68
- 52 Week High
- AMAL $38.19
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- AMAL 36.06
- REPL 29.00
- Support Level
- AMAL $29.29
- REPL $3.02
- Resistance Level
- AMAL $33.36
- REPL $3.85
- Average True Range (ATR)
- AMAL 0.86
- REPL 0.76
- MACD
- AMAL -0.48
- REPL -0.91
- Stochastic Oscillator
- AMAL 11.19
- REPL 10.13
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.